Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners

Business

Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners

2025-11-18 13:59 Last Updated At：14:57

AMSTERDAM--(BUSINESS WIRE)--Nov 18, 2025--

Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117345890/en/

The announcement follows a record-breaking Q3 2025 for Avanzanite, with revenue tripling year-on-year and climbing over 20% quarter-on-quarter. This strategic funding will accelerate the expansion of Avanzanite’s pan-European infrastructure and propel both current and future rare disease product launches. The capital will also enable Avanzanite to form new strategic alliances and acquire assets to expand its portfolio.

Avanzanite was built to solve Europe’s rare-disease medicines access gap. Under one pan-European operation, Avanzanite brings together commercial excellence, scientific expertise, and deep functional capability across market access, pricing and reimbursement. This fully integrated approach enables biotech and pharma innovators to bring rare disease medicines to patients across all 32 European markets – an area where traditional go-to-market models often fail.

“We are truly honoured to partner with MVM, a top-tier investor in life sciences. Their investment is far more than capital – it demonstrates conviction in our mission and belief in the ‘Champions League’ team that powers Avanzanite,” said Adam Plich, Founder and CEO of Avanzanite. “With MVM’s support we will scale faster, expand with new partnerships and assets, and advance towards our 2032 vision of a pan-European platform with more than ten rare disease alliances – setting a new European standard for orphan medicine commercialisation and patient access. While this milestone reflects how far we’ve come, it is just the beginning of our journey,” concluded Plich.

In just three years, with three strategic alliances, Avanzanite has become the partner of choice for biotech and pharma innovators seeking to unlock the full European potential of their orphan medicines. Avanzanite’s current portfolio comprises three medicines across nephrology, ophthalmology and haematology with exclusive licensing or distribution rights in countries across the European Economic Area, the UK and Switzerland.

MVM is investing up to €32 million from its €500 million sixth fund. In addition, MVM has reserved significant capital to drive Avanzanite’s growth beyond the current round. MVM is Avanzanite’s first institutional investor and joins the company’s Board of Directors.

Dr. Jack Tanaka, Partner at MVM commented, “For years MVM has watched promising rare disease medicines struggle to find a path to patients - Avanzanite breaks this pattern. In a short space of time, Avanzanite has successfully launched multiple rare disease products. Their experienced leadership team and pan-European footprint make them the stand-out partner. We are excited to support Avanzanite in bringing more transformative therapies to patients across Europe.”

About Avanzanite Bioscience

Avanzanite redefines launches of rare disease medicines across Europe. Founded in 2022 and based in Amsterdam, the Netherlands, we partner with biotech and pharma innovators to unlock the full value of orphan medicines continent-wide. With our deep expertise in market access, we navigate Europe’s complex landscape like master chess players – ensuring no patient is left behind while rewarding biotech and pharma innovators for their commitment to developing breakthrough therapies. For more information, visit www.avanzanite.com

About MVM Partners

MVM has invested in high-growth healthcare businesses since 1997. With teams in Boston, London and the San Francisco Bay Area, MVM has a broad, global investment outlook spanning medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, digital health, and other sectors of healthcare. More information can be found at www.mvm.com

A first repatriation flight brings stranded French citizens home as war in Iran disrupts travel

PARIS (AP) — The first flight repatriating French citizens stranded in the Middle East because of the war in Iran landed in Paris early Wednesday.

French authorities booked about 100 seats onboard for vulnerable people on a priority list, the minister responsible for French Nationals Abroad, Eleonore Caroit, said. The plane departed from Muscat, Oman and made a stop in Cairo, Egypt, before touching down at Paris Charles de Gaulle airport, as travel across the region remains heavily disrupted by the widening conflict.

A second flight carrying French citizens, who were based in Israel and managed to cross the border with Egypt, should arrive in France later Wednesday, Caroit said.

“We are focusing on a priority group — families with children, people affected by illness, old people,” she told TF1 broadcaster. “Our goal is to help repatriate as quickly as possible the French people who wish to return.”

French President Emmanuel Macron said an estimated 400,000 French people are present in the region affected by the conflict, either as residents or temporarily passing through.

With airspace closed or heavily restricted across much of the Gulf, passengers have been stranded not only in the region but also in cities far from the fighting after their connecting flights were canceled. Amid the travel chaos and with commercial flights limited, governments across the globe have been mounting emergency operations to try to repatriate their citizens.

The United States told American citizens to leave more than a dozen countries in the region right away using any available commercial transportation. The countries include Iran and Israel, as well as Qatar, Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Oman, the Palestinian territories, Saudi Arabia, Syria, the United Arab Emirates and Yemen.

In Europe, the British government said a chartered flight will take off from Oman late Wednesday to bring back some of the thousands of U.K. nationals in the Gulf. It said the most vulnerable will be prioritized for the first of what is expected to be a series of flights.

The Foreign Office said more than 130,000 British nationals in the Middle East have registered their presence with the government since the U.S.-Israel-Iran conflict broke out, though not all are trying to leave. Many of those are in the UAE, and the government has advised against trying to travel overland to Oman.

Commercial airlines are also starting to resume some flights, with Etihad, Emirates and Virgin Atlantic all due to operate flights from the UAE to London on Wednesday.

Elsewhere, Norway’s Foreign Ministry said it’s sending an “emergency team” to Dubai to reinforce the Norwegian embassy’s team helping an estimated 1,500 Norwegians registered in the city.